Joanna Mączewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joanna Mączewska has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jarosław Marusiak
Department of Kinesiology, Faculty of Physiotherapy, Wroclaw University of Health and Sport Science, Wroclaw, Poland
1 shared publication - Karolina Lorek
Department of Kinesiology, Wroclaw University of Health and Sport Sciences, Paderewskiego 35 Avenue, 51-612 Wrocław, Poland
1 shared publication - Katarzyna Dobruch-Sobczak
Radiology Department II, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland
1 shared publication - Katarzyna Kisiel-Sajewicz
Department of Kinesiology, Faculty of Physiotherapy, University School of Physical Education in Wrocław, Wrocław, Poland
1 shared publication - Katarzyna Roszkowska-Purska
Department of Pathomorphology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-034 Warsaw, Poland
1 shared publication - Leszek Królicki
Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland
1 shared publication
Latest Publications
- 3 October 2023
- Published by Wiley in European Journal of Neuroscience
- Vol. 58 (9) , 4070-4083
Slowing of EEG waves correlates with striatal [18F]fluorodopa PET/CT uptake and executive dysfunction in Parkinson's disease
Parkinson's disease (PD) research on specific neuroimaging and neurophysiological biomarkers revealing executive dysfunction mechanisms is limited, necessitating validation. Thus, our study aimed to assess associations between electroencephalographic power spectral density (PSD‐EEG), striatal [18F]Fluorodopa uptake and neuropsychological executive function (EF) testing parameters in PD, while also estimating their diagnostic accuracy. We compared resting PSD‐EEG, striatal [18F]Fluorodopa uptake ratios based on positron emission computed tomography ([18F]FDOPA PET/CT) and neuropsychological EF tests outcomes [Trail Making Test (TMT) and Stroop Test (ST)] between PD patients and healthy controls (HCO) and then calculated correlations among these measures separately for each group. Additionally, we estimated PD diagnostic accuracy of the PSD‐EEG and [18F]FDOPA PET/CT parameters. In PD patients, we observed the following: (i) slower EEG waves, reflected in increased power of the EEG theta and lower‐alpha bands in frontal lobe areas; (ii) reduced [18F]FDOPA PET/CT uptake in the putaminal and caudate nuclei, along with a decreased putamen‐to‐caudate ratio ([18F]FDOPA PET/CT PCR); and (iii) longer performance times evident in nearly all EF tests' parameters. Slower EEG waves correlated negatively with [18F]FDOPA PET/CT PCR and positively with most of the EF test parameters. Furthermore, we found negative correlations between [18F]FDOPA PET/CT PCR and certain EF measures related to ST. [18F]FDOPA PET/CT ratios and several PSD‐EEG parameters, particularly those from the prefrontal cortex, demonstrated clinically reasonable diagnostic accuracy for PD. In conclusion, EEG waves slowing in the frontal lobe were correlated with striatal dopaminergic deficiency and impaired executive function in mild PD patients and showed promise as a biomarker of PD‐related executive dysfunction.
- 3 October 2023
- Published by Wiley in European Journal of Neuroscience
- Vol. 58 (9) , 4070-4083
Slowing of EEG waves correlates with striatal [18F]fluorodopa PET/CT uptake and executive dysfunction in Parkinson's disease
Parkinson's disease (PD) research on specific neuroimaging and neurophysiological biomarkers revealing executive dysfunction mechanisms is limited, necessitating validation. Thus, our study aimed to assess associations between electroencephalographic power spectral density (PSD‐EEG), striatal [18F]Fluorodopa uptake and neuropsychological executive function (EF) testing parameters in PD, while also estimating their diagnostic accuracy. We compared resting PSD‐EEG, striatal [18F]Fluorodopa uptake ratios based on positron emission computed tomography ([18F]FDOPA PET/CT) and neuropsychological EF tests outcomes [Trail Making Test (TMT) and Stroop Test (ST)] between PD patients and healthy controls (HCO) and then calculated correlations among these measures separately for each group. Additionally, we estimated PD diagnostic accuracy of the PSD‐EEG and [18F]FDOPA PET/CT parameters. In PD patients, we observed the following: (i) slower EEG waves, reflected in increased power of the EEG theta and lower‐alpha bands in frontal lobe areas; (ii) reduced [18F]FDOPA PET/CT uptake in the putaminal and caudate nuclei, along with a decreased putamen‐to‐caudate ratio ([18F]FDOPA PET/CT PCR); and (iii) longer performance times evident in nearly all EF tests' parameters. Slower EEG waves correlated negatively with [18F]FDOPA PET/CT PCR and positively with most of the EF test parameters. Furthermore, we found negative correlations between [18F]FDOPA PET/CT PCR and certain EF measures related to ST. [18F]FDOPA PET/CT ratios and several PSD‐EEG parameters, particularly those from the prefrontal cortex, demonstrated clinically reasonable diagnostic accuracy for PD. In conclusion, EEG waves slowing in the frontal lobe were correlated with striatal dopaminergic deficiency and impaired executive function in mild PD patients and showed promise as a biomarker of PD‐related executive dysfunction.
- Open Access
- 19 November 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (22) , 5394
Is There a Correlation between Multiparametric Assessment in Ultrasound and Intrinsic Subtype of Breast Cancer?
Molecular profile of breast cancer provides information about its biological activity, prognosis and treatment strategies. The purpose of our study was to investigate the correlation between ultrasound features and molecular subtypes of breast cancer. From June 2019 to December 2019, 86 patients (median age 57 years; range 32–88) with 102 breast cancer tumors were included in the study. The molecular subtypes were classified into five types: luminal A (LA), luminal B without HER2 overexpression (LB HER2−), luminal B with HER2 overexpression (LB HER2+), human epidermal growth factor receptor 2 positive (HER2+) and triple negative breast cancer (TNBC). Histopathological verification was obtained in core biopsy or/and post-surgery specimens in all cases. Univariate logistic regression analysis was performed to assess the association between the subtypes and ultrasound imaging features. Experienced radiologists assessed lesions according to the BIRADS-US lexicon. The ultrasound scans were performed with a Supersonic Aixplorer and Supersonix. Based on histopathological verification, the rates of LA, LB HER2−, LB HER2+, HER2+, and TNBC were 33, 17, 17, 16, 19, respectively. Both LB HER2+ and HER2+ subtypes presented higher incidence of calcification (OR = 3.125, p = 0.02, CI 0.0917–5.87) and HER2+ subtype presented a higher incidence of posterior enhancement (OR = 5.75, p = 0.03, CI 1.2257–32.8005), compared to other subtypes. The calcifications were less common in TNBC (OR = 0.176, p = 0.0041, CI 0.0469–0.5335) compared to other subtypes. There were no differences with regard to margin, shape, orientation, elasticity values and vascularity among five molecular subtypes. Our results suggest that there is a correlation between ultrasonographic features assessed according to BIRADS-US lexicon and BC subtypes with HER2 overexpression (both LB HER2+ and HER2+). It may be useful for identification of these aggressive subtypes of breast cancer.
- 19 November 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (22) , 5394
Open AccessIs There a Correlation between Multiparametric Assessment in Ultrasound and Intrinsic Subtype of Breast Cancer?
Molecular profile of breast cancer provides information about its biological activity, prognosis and treatment strategies. The purpose of our study was to investigate the correlation between ultrasound features and molecular subtypes of breast cancer. From June 2019 to December 2019, 86 patients (median age 57 years; range 32–88) with 102 breast cancer tumors were included in the study. The molecular subtypes were classified into five types: luminal A (LA), luminal B without HER2 overexpression (LB HER2−), luminal B with HER2 overexpression (LB HER2+), human epidermal growth factor receptor 2 positive (HER2+) and triple negative breast cancer (TNBC). Histopathological verification was obtained in core biopsy or/and post-surgery specimens in all cases. Univariate logistic regression analysis was performed to assess the association between the subtypes and ultrasound imaging features. Experienced radiologists assessed lesions according to the BIRADS-US lexicon. The ultrasound scans were performed with a Supersonic Aixplorer and Supersonix. Based on histopathological verification, the rates of LA, LB HER2−, LB HER2+, HER2+, and TNBC were 33, 17, 17, 16, 19, respectively. Both LB HER2+ and HER2+ subtypes presented higher incidence of calcification (OR = 3.125, p = 0.02, CI 0.0917–5.87) and HER2+ subtype presented a higher incidence of posterior enhancement (OR = 5.75, p = 0.03, CI 1.2257–32.8005), compared to other subtypes. The calcifications were less common in TNBC (OR = 0.176, p = 0.0041, CI 0.0469–0.5335) compared to other subtypes. There were no differences with regard to margin, shape, orientation, elasticity values and vascularity among five molecular subtypes. Our results suggest that there is a correlation between ultrasonographic features assessed according to BIRADS-US lexicon and BC subtypes with HER2 overexpression (both LB HER2+ and HER2+). It may be useful for identification of these aggressive subtypes of breast cancer.